





Combined HRT patches – Ongoing Shortages and Alternatives

All combined HRT patches remain unavailable. Supplies of Evorel Conti/Sequi and FemSeven Conti/Sequi are expected to resume at the end of Q1 2020. In the mean-time following alternatives could be considered depending on the route of administration:

Continuous combined HRT patch alternatives

- 1. Estradiol 50 mcg **patch** (e.g. Estradot 50, Estraderm 50 or Progynova TS 50) <u>PLUS</u> Micronised progesterone 100mg caps (e.g. Ultrogestan) one each night.
- 2. Estradiol 50 mcg **patch** (e.g. Estradot 50, Estraderm 50 or Progynova TS 50) <u>PLUS</u> IUD Mirena (replaced after 4 years when used for oestrogen replacement therapy).
- 3. Estradiol transdermal **gel** (e.g. Oestrogel 2 actuations or Sandrena 1mg <u>PLUS</u> Micronised progesterone 100mg caps (e.g. Ultrogestan) one each night.
- 4. Estradiol transdermal **gel** (e.g. Oestrogel 2 actuations or Sandrena 1mg <u>PLUS</u> IUD Mirena (replaced after 4 years when used for oestrogen replacement therapy).
- 5. Oral combined continuous **tablets** containing 2mg Estradiol (e.g. Kliofem, Elleste Duet Conti)

Cyclical combined HRT patch alternatives

- Estradiol 50 mcg patch (e.g. Estradot 50, Estraderm 50 or Progynova TS 50) PLUS
 Micronised progesterone 100mg caps (e.g. Ultrogestan) 200mg orally at bedtime for 12 days each
 28 day cycle.
- 2. Estradiol transdermal **gel** (e.g. Oestrogel 2 actuations or Sandrena 1mg PLUS Micronised progesterone 100mg caps (e.g. Ultrogestan) 200mg orally at bedtime for 12 days each 28 day cycle.
- 3. Oral combined cyclical tablets containing 2mg Estradiol (e.g. Elleste Duet 2mg)

NICE publish Cannabis-based medicinal products guideline

The guideline covers prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy.

All prescribing should remain specialist prescribed.

A summary of the recommendations is:

- Consider nabilione as an add-on treatment for adults (18 years and over) with chemotherapyinduced nausea and vomiting which persists with optimised conventional antiemetics.
- Do Not offer cannabis-based products for the management of chronic pain
- THC:CBD spray (Sativex) can be offered for moderate to severe spasticity in adults with multiple sclerosis under certain circumstances
- More research is required for NICE to make recommendations on the use of cannabis-based medicinal products for severe treatment-resistant epilepsy.

Further information can be found here: https://www.nice.org.uk/quidance/nq144/chapter/Recommendations

<u>Updated Erectile Dysfunction Guidelines</u>

The New Erectile dysfunction guideline can be found in the Top Tips section of the CCG internet site here: http://www.rotherhamccg.nhs.uk/ED%20pathway%20%202019v4.pdf

ERECTILE DYSFUNCTION (ED) presented in primary Clinical Commissioning Group INVESTIGATIONS History Abnormal Physical examination to exclude peripheral arterial disease, testosterone hypogonadism, prostate abnormalities, local external penis Nmol/L Age<50: <10 Investigate known risk factors (CV, DM, lipids, smoking, alcohol, 50-75: <9 75+: <8 Bloods: testosterone, serum lipids and fasting glucose OR HbA1C Testosterone abnormal Testosterone normal Repeat testosterone with an early TREATMENT morning level and: PDE5 inhibitor - FSH/LH Discuss treatment goals, expectations and SLS criteria Inform PDE5i requires sexual stimulation (not an initiator) PROLACTIN if testosterone <5 Titrate up and try on 8 different occasions at max FBC including hematocrit dose before classed as non-responder Review 6-12 monthly Ensure no CONTRAINDICATIONS: concomitant nitrates in any form, guanylate cyclase stimulators, potent CYP3A4 inhibitors, hypotension, Non-Arteritic Anterior Ischemic Testosterone Abnormal: Optic Neuropathy , severe renal or hepatic impairment 1st line: SILDENAFIL (generic only) PRN normal: REFER to Usually starting at 50mg and increasing to 100mg if PDE5 inhibitor ENDOCRINOLOGY

Scriteria

restricted to SLS.

All other treatments for ED can only be provided on PRIVATE PRESCRIPTION unless, patient meets SLS criteria: • diabetes • post-prostatectomy • renal failure treated by transplant or dialysis • spinal cord injury • single gene neurological disease • radical pelvic surgery • prostate cancer • multiple sclerosis • poliomyelitis • spina bifida • parkinsons disease • severe pelvic injury • NHS patients treated for ED before 14.9.98. Severe distress is no longer listed SLS criterion.

2nd line: generic TADALAFIL 10/20mg PRN dose

ineffective, or decreasing to 25mg if needed.

Provide NHS prescription for all ED patients, not

Private Rx unless patient is eligible for NHS treatment as above. Daily formulations 2.5mg and 5mg not to be prescribed on NHS.

QUANTITIES: One treatment per week will be appropriate for most patients – prescribe 4 tablets per month.

However, the maximum frequency of once per day may be prescribed on NHS by a GP if required and clinically appropriate.

REFER to UROLOGY if:

- Failure of both PDE5 inhibitors AND
- Patient meeting SLS criteria for NHS treatment and requiring other treatment options:
- vacuum erection devices*
- intracavernous injection
- intraurethal application
- topical cream
- penile prosthesis

Common choice of cost effective vacuum erection devices initiated in Rotherham: Rapport Classic SM2000 by Owen Mumford Ltd or Farnhurst Elite ES101 by R and G Products Ltd. Corresponding replacement rings to be prescribed by GP when required – refer to urology clinic letter for recommended brand and size for each patient.

Date approved: November 2019 • Review by November 2021 • Lidia Borak Medicines Management Team